Annals of Surgical Oncology Sign the Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Medary, I.
Right arrow Articles by La Quaglia, M. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Medary, I.
Right arrow Articles by La Quaglia, M. P.

Annals of Surgical Oncology, Vol 3, Issue 6 521-525, Copyright © 1996 by Society of Surgical Oncology

ARTICLES

Kinetics of primary tumor regression with chemotherapy: implications for the timing of surgery

I. Medary, D. Aronson, N. K. Cheung, F. Ghavimi, W. Gerald and M. P. La Quaglia
Department of Pediatric Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.

PURPOSE: The kinetics of tumor regression during administration of chemotherapy has relevance to the timing of surgery. The aim of this study was characterization of the time course of primary tumor regression in initially unresectable rhabdomyosarcoma, hepatoblastoma, and neuroblastoma patients. We also estimated the total cell number in the primary tumor at diagnosis. METHODS: Tumor volumes of 24 pediatric patients with either unresectable rhabdomyosarcoma, hepatoblastoma, or neuroblastoma were determined by using computerized three-dimensional reconstruction from serial computed tomography (CT) scans during chemotherapy. Cell densities were calculated by counting cell numbers in high-power fields and dividing by area and section thickness. Cell number at diagnosis was then calculated. RESULTS: Median tumor volumes at diagnosis were 175 cc, 748 cc, and 738 cc for rhabdomyosarcoma, neuroblastoma, and hepatoblastoma, respectively. The median tumor cell counts were 31, 68, and 59 x 10(10) cells/tumor for rhabdomyosarcoma, neuroblastoma, and hepatoblastoma, respectively. The tumor regression was most rapid during the first two cycles, and little change in volume was observed after three cycles. CONCLUSION: Rapid initial reduction in primary tumor volume with chemotherapy was observed in rhabdomyosarcoma, neuroblastoma, and hepatoblastoma. These data suggest that second-look resection may be feasible after two to three cycles of chemotherapy. This hypothesis may be tested by randomizing the timing of second-look surgical intervention.


This article has been cited by other articles:


Home page
 JCOHome page
L. B. Faulkner, A. Garaventa, A. Paoli, V. Tintori, A. Tamburini, L. Lacitignola, M. Veltroni, M. S. L. Piccolo, E. Viscardi, C. Milanaccio, et al.
In Vivo Cytoreduction Studies and Cell Sorting-Enhanced Tumor-Cell Detection in High-Risk Neuroblastoma Patients: Implications for Leukapheresis Strategies
J. Clin. Oncol., November 15, 2000; 18(22): 3829 - 3836.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by the Society of Surgical Oncology.